The late stage chronic kidney disease drugs market was valued at US$ 4,680.0 million in 2019 and is projected to reach US$ 11,096.9 million by 2027; it is expected to grow at a CAGR of 11.6% from 2020 to 2027.
Late-stage renal disease, also called end-stage kidney disease, occurs when chronic kidney disease (the gradual loss of kidney function) reaches an advanced state. In end-stage renal disease, kidneys are no longer able to work as they should to meet the body's needs. At this advanced stage, the kidney loses all its ability to function effectively, and eventually dialysis or a kidney transplant is needed to save the life. High prevalence of diseases leading to chronic kidney diseases and favorable reimbursement policy for the late stage chronic kidney disease drugs are the major factor propelling the market growth. However, delay in the diagnosis of chronic kidney disease is expected to hamper the growth of the market up to certain extent during the forecast period.
Lucrative Regions for Late Stage Chronic Kidney Disease Drugs Market
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
Market Insights
High Prevalence of Diseases Leading to Chronic Kidney Diseases
Chronic kidney disease (CKD) is a common and life-threatening condition that affects 1 in 10 people worldwide. It affects more than 26 million Americans and millions more worldwide. High blood pressure and diabetes were the two major causes in 75% of kidney failure cases between 2015 and 2017. 47% of new end-stage kidney disease (ESKD) patients had a primary diagnosis of diabetes, while 29% of new end-stage kidney disease patients had a primary diagnosis of hypertension. Moreover, according to Bayer's press release, about 29 million people in the US have type 2 diabetes, and 40% will develop CKD in the coming year.
According to the CDC, 1 in 3 adults with diabetes and 1 in 5 adults with high blood pressure might have chronic kidney disease. In 2015, 30.3 million people in the US had diabetes as per the American Diabetes Association (ADA). According to the CDC, in 2014, around 118,000 people in the US have started the treatment for end-stage renal disease, and the number of people for treatment is expected to increase as more people become aware of this condition. Moreover, the CDC states that around 96% of the people with kidney damage are not aware of having chronic kidney disease, which indicates the underlying market prospective in the late stage of chronic kidney disease drugs. These factors are expected to enhance market growth during the forecast period.
As per the National Kidney Foundation Inc., chronic kidney disease causes more deaths than prostate cancer or breast cancer. It is an under-recognized emergency health condition among people. It affects an estimated 26 million people in the US (15% of the adult population; more than 1 in 7 adults). 1 in 3 American adults (about 80 million people) is at risk due to CKD. CKD is more common in women than in men. It is the 9th leading cause of death in the US. Glomerulonephritis (diseases that damage the kidney's filtering units); inherited diseases, such as polycystic kidney disease; malformations during the development of fetus; lupus and other immune diseases; obstructions such as kidney stones or an enlarged prostate; and repeated urinary tract infections are among the other conditions that can lead to ESKD.
Introduction of New Preclinical Models to Improve Target Validation and Understand Disease Development
Manufactures are in a stronger position than ever before to look for targets and treatments and now they have a deeper molecular understanding of CKD. Various manufacturers are investing in the development of sophisticated models that mimic the human kidney accurately than has ever previously been possible. It is impossible to virtually imitate the functions of kidney in classical in vitro systems, while in vivo models; it is intensive to produce, and not always adaptable to human systems. 3D bioprinting and organs-on-chips are the new model systems that the manufacturers in the market are embedding into their research pipeline to bridge this gap. With these groundbreaking techniques, they can test compound behavior and hope to understand disease mechanisms in a subtle way.
Organs-on-Chip technology provides environments that emulate major aspects of the real kidney physiology; including fluidic channels that are lined with living cells in the accurate structural design. The flow represents the flow of blood carrying nutrients, takes away waste products, and also creates mechanical forces, all critical factors for the functioning of the kidney.
In 2018, Emulate, Inc. has formed a collaborative partnership with AstraZeneca’s Innovative Medicines and Early Development (IMED) Biotech Unit to drive in its Organs-on-Chips technology within the laboratories of the IMED Drug Safety organization. As part of the agreement, Emulate plans to co-locate scientists within AstraZeneca’s laboratories. The aim of this agreement is to speed up the development of Organs-on-Chips technology and testing within the context of a pharmaceutical organization. Further, in March 2020, the company announced that it has completed the 150th installation of its Zoë instrument, part of a lab-ready platform for Organs-on-Chips technology for use by researchers across various industries. Additionally, the limited number of treatment options for kidney patients is strongly linked to the lack of translatable systems as there is a high attrition rate with kidney candidate drugs in clinical trials. Organs-on-Chip technology could help solve this challenge.
Product Type-Based Insights
Based on product type, the late stage chronic kidney disease drugs market is segmented into calcimimetics, vitamin D, potassium binders, calcium-based phosphate binders, and others. The calcimimetics segment held the highest share of the late stage chronic kidney disease drugs market in 2019 and is estimated to register the highest CAGR of 12.1% in the market during the forecast period. Calcimimetics are commonly used in patients on dialysis to treat secondary hyperparathyroidism. Mineral and bone disorders (MBD) are the common complications of chronic kidney disease (CKD), which are significant risk factors in mortality in CKD patients. Cinacalcet, the only available calcimimetic, is a useful therapeutic in CKD-MBD. Various clinical trials with cinacalcet in hemodialysis patients with SHPT have shown a reduction in parathyroid hormone, phosphate (P), calcium (Ca), and Ca x P product levels more tremendous success in reaching therapeutic goals as per the recommendations of international guidelines. Additionally, some studies have shown that cinacalcet may improve other aspects of CKD-MBD, and reduces the risk of parathyroidectomy and vascular calcification, among others. Secondary hyperparathyroidism (SHPT) is a highly prevalent and crucial complication in patients with chronic kidney disease (CKD). Calcimimetic agents may help control SHPT and achieve the though mineral metabolism targets in patients with late stage chronic kidney disease.
Calcimimetics act by suppressing the secretion of parathyroid hormone by sensitizing the parathyroid calcium receptor to serum calcium. calcimimetics in combination with a higher dose of a calcium-based oral phosphate binder is an effective and well-tolerated alternative for the standard treatments such as vitamin D derivatives in combination with a non-calcium-based oral phosphate binder.
For instance, in February 2017, Amgen received the approval for Parsabiv: an etelcalcetide from US Food and Drug Administration (FDA), for the treatment of secondary hyperparathyroidism (HPT) in adult patients with late stage chronic kidney disease receiving hemodialysis. Parsabiv is the first therapy approved for HPT in ESRD in 12 years. It is the only calcimimetic that used for intravenous administration by the dialysis health care team thrice a week to the ending of the hemodialysis session.
Global Late Stage Chronic Kidney Disease Drugs Market, by Product Type– 2019 & 2027
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
Indication-Based Insights
Based on indication, the late stage chronic kidney disease drugs market is segmented into late stage chronic kidney disease induced hyperparathyroidism, late stage chronic kidney disease induced hyperphosphatemia, and late stage chronic kidney disease induced hyperkalemia. End-stage renal disease (ESRD) patients are at high risk for hyperkalemia, especially when other factors and comorbidities that interfere with renal potassium excretion are present. The prevalence of hyperkalemia in CKD patients is considerably higher than in the general population. Chronic hyperkalemia is a major concern in ESRD patients, especially for those who administer RAAS blockades for cardiac disease and/or diabetes. Potassium binding agents are useful in maintaining the serum potassium in the normal range without lowering the dose or discontinuing RAAS inhibitors and restricting the intake of vegetables and fruits.
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Late Stage Chronic Kidney Disease Drugs Market: Strategic Insights
Market Size Value in US$ 4,680.0 Million in 2019 Market Size Value by US$ 11,096.9 Million by 2027 Growth rate CAGR of 11.6% from 2020-2027 Forecast Period 2020-2027 Base Year 2020
Akshay
Have a question?
Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Late Stage Chronic Kidney Disease Drugs Market: Strategic Insights
| Market Size Value in | US$ 4,680.0 Million in 2019 |
| Market Size Value by | US$ 11,096.9 Million by 2027 |
| Growth rate | CAGR of 11.6% from 2020-2027 |
| Forecast Period | 2020-2027 |
| Base Year | 2020 |
Akshay
Have a question?
Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Product launches and expansion strategies are commonly adopted by the companies to expand their footprint worldwide, meet the growing demand, and increase its product portfolio.
The key players operating in the late stage chronic kidney disease drugs market adopted the strategy of product innovation to cater to changing customer demand across the world, which also permits the players to maintain their brand name globally.
By Product Type
- Calcimimetics
- Vitamin D
- Sterols
- Potassium Binders
- Calcium-Based Phosphate Binders
By Indication
- Late Stage Chronic Kidney Disease Induced Hyperparathyroidism
- Late Stage Chronic Kidney Disease Induced Hyperphosphatemia
- Late Stage Chronic Kidney Disease Induced Hyperkalaemia
By Distribution Channel
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
By Geography
- North America
- US
- Canada
- Mexico
- Europe
- France
- Germany
- Italy
- UK
- Spain
- Asia Pacific (APAC)
- China
- India
- South Korea
- Japan
- Australia
- Middle East & Africa (MEA)
- South Africa
- Saudi Arabia
- UAE
- South and Central America (SCAM)
- Brazil
- Argentina
Company Profiles
- Abbvie Inc.
- Amgen
- Astrazeneca
- Sanofi S.A.
- Kyowa Kirin Co., Ltd
- Takeda Pharmaceutical Company Limited
- Astellas Pharma Inc.
- Bayer Ag
- Vifor Pharma Management Ltd.
- Akebia Therapeutics, Inc.
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
Product Type ; Indication ; Distribution Channel , and Geography
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
Argentina, Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Saudi Arabia, South Africa, South Korea, Spain, United Arab Emirates, United Kingdom, United States
Frequently Asked Questions
Late-stage renal disease, also called end-stage kidney disease, occurs when chronic kidney disease (the gradual loss of kidney function) reaches an advanced state. In end-stage renal disease, kidneys are no longer able to work as they should to meet the body's needs. At this advanced stage of kidney disease, the kidneys have lost nearly all their ability to do their job effectively, and eventually dialysis or a kidney transplant is needed to live. Few classes of drugs are specifically used for the treatment of late stage chronic kidney disease are known as late stage chronic kidney disease drugs.
The factors that are driving growth of the market are high prevalence of diseases leading to chronic kidney diseases and favorable reimbursement policy for the late stage chronic kidney disease drugs are expected to boost the growth of the global late stage chronic kidney disease drugs market.
The late stage chronic kidney disease drugs market majorly consists of the players such AbbVie Inc., Amgen, AstraZeneca, Sanofi, Kyowa Kirin Co., Ltd., Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., Bayer AG, Vifor Pharma Management Ltd., and Akebia Drugs, Inc. among others.
The List of Companies - Late Stage Chronic Kidney Disease Drugs Market
- AbbVie Inc.
- Amgen
- AstraZeneca
- Sanofi
- Kyowa Kirin Co., Ltd.
- Takeda Pharmaceutical Company Limited
- Astellas Pharma Inc.
- Bayer AG
- Vifor Pharma Management Ltd.
- Akebia Drugs, Inc.
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Trends and growth analysis reports related to Late Stage Chronic Kidney Disease Drugs Market
Sep 2020
Aquatic Veterinary Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Diagnostics and Treatments), Species (Fish, Crustaceans, Mollusca, and Others), Disease Source (Bacteria, Viruses, Parasites, and Others), Route of Administration (Water Medication, Medicated Feed, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Sep 2020
Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis By Treatment (Generic Drugs and Originators), Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Sep 2020
Malaria and Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Treatment [Malaria and Sickle Cell Disease (SCD)], Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Sep 2020
Pharmaceutical Contract Sales Organizations Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Services (Commercial Services and Non-Commercial Services), Modules (Syndicated Modules and Dedicated Modules), Therapeutic Area (Cardiovascular Disorders, Oncology, Metabolic Disorders, Neurology, Orthopedic Diseases, Infectious Diseases, and Others), End User (Biopharmaceutical Companies and Pharmaceutical Companies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Sep 2020
Breast Cancer Therapeutics Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Drug Therapy [Targeted Drug Therapy (Abemaciclib, Ado-Trastuzumab Emtansine, Palbociclib, Trastuzumab, and Other Target Drug Therapies), Hormonal Drug Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, and Selective Estrogen Receptor Downregulators), Chemotherapy, and Immunotherapy/Biological Therapy], Breast Cancer Type (Hormone Receptor, HER2+, and Triple-Negative Breast Cancer), Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, and Online Pharmacies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Sep 2020
Radioactive Tracer Market
Size and Forecast to 2030 - Global Analysis by Tracer Type [Technetium-99m & Tc-97m, Iodine-131, Iron-59, Lutetium-171, Rubidium (Rb-82) Chloride & Ammonia (N-13), Scandium-46, Seaborgium-269, Hassium-269, Gallium Citrate Ga 67, Prostate-Specific Membrane Antigen (PSMA) (Ga-68), FDDNP (F-18) & FDOPA (F-18), Phosphorus-32 & Chromium-51, Thallium-201, F-18 FDG, F-18 FAPI, Ga-68 FAPI, F-18 PSMA, DOTATOC/DOTANOC/DOTATATE (Ga-68), and Others], Test Type (PET, SPECT, and Others), Application (Oncology, Pulmonary, Neurology, Cardiology, and Others) End User (Hospitals & Clinics, Diagnostic Centers, Academic & Research Institutes, And Others), and Geography
Sep 2020
Glioma Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Disease (Astrocytoma, Oligoastrocytoma, and Oligodendroglioma), Treatment Type (Surgery, Chemotherapy, Radiation Therapy, and Others), Grade (Low Grade and High Grade), End User (Hospital & Clinics and Ambulatory Surgical Center), and Geography
Sep 2020
Drug Delivery Market
Forecast to 2028 - Global Analysis By Route of Administration (Injectable Drug Delivery, Oral Drug Delivery, Transmucosal Drug Delivery, Topical Drug Delivery, Implantable Drug Delivery, and Ocular Drug Delivery), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and End User (Hospitals and Clinics, Home Care Settings, and Other End User)